Compare ResMed Inc. (RMD) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Upwork Inc — how do they compare? ResMed Inc. trades at $225 (market cap $32.61B), while Upwork Inc trades at $8.37 (market cap $1.04B). The key difference: ResMed Inc. is far larger — about 31.4× Upwork Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| RMD | UPWK | |
|---|---|---|
Market Cap | $32.61B | $1.04B |
Sector | Health | Industrials |
52-Week High | $293.73 | $22.11 |
52-Week Low | $182.82 | $7.84 |
Enterprise Value | $31.97B | $806.15M |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Upwork (UPWK) stock is trading at $8.385, down 14.7% on the day following Q2 2026 results. While the company beat earnings expectations with EPS of $0.41 versus $0.3424, weak forward guidance triggered the sell-off. The stock exhibits a bearish technical signal, trading near key support levels. Fundamentally, the company maintains solid profitability metrics, including a 77.21% gross margin and a P/E ratio of 10.71, but faces headwinds from declining active client counts and AI-related market shifts.
The outlook is cautious. Analyst consensus remains a 'Buy' with a $9.25 price target, suggesting potential upside from current levels. However, near-term risks are elevated due to the guidance miss, ongoing client attrition, and potential legal investigations. The stock's valuation appears reasonable, but investor confidence hinges on the company's ability to stabilize client growth and navigate the AI disruption in the freelance market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
